AN6.F AnaptysBio Inc.
- Market cap
- EUR 1.28B
- P/E
- -
- P/B
- 133.77x
- ROE
- -1,659.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2026.
Is AN6.F undervalued?
Graham numberThe Graham number of AnaptysBio Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
AnaptysBio Inc. fundamental analysis
No fundamental analysis for AnaptysBio Inc. yet.
AnaptysBio Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About AnaptysBio Inc.
AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agr…
Full company profileAnaptysBio Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Mar 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
AnaptysBio Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 63.2M | 10.3M | 17.2M | 91.3M | 235M | 102M |
| Operating Income | -56.8M | -115M | -157M | 66.2M | 227M | -139M |
| EBITDA | - | -105M | -143M | 83.0M | 244M | -126M |
| Net Income | -57.8M | -129M | -164M | -145M | -13.2M | -212M |
| EPS | -2.09 | -4.51 | -6.15 | -4.77 | -0.47 | -7.29 |
| Balance Sheet | ||||||
| Total Assets | 643M | 610M | 452M | 484M | 364M | 330M |
| Total Liabilities | 287M | 348M | 364M | 413M | 327M | 317M |
| Shareholders' Equity | 356M | 262M | 88.1M | 70.9M | 37.2M | 12.7M |
| Cash & Short-term Investments | 496M | 71.3M | 36.0M | 123M | 238M | 248M |
| Cash Flow | ||||||
| Operating Cash Flow | -45.9M | -73.6M | -121M | -135M | 19.7M | -104M |
| Capital Expenditure | 1.37M | 358K | 807K | 358K | 87.0K | 68.0K |
| Free Cash Flow | -47.3M | -74.0M | -122M | -135M | 19.7M | -104M |
| Ratios | ||||||
| ROE | -16.2% | -49.1% | -185.7% | -204.9% | -35.6% | -1,659.5% |
| ROA | -9.0% | -21.1% | -36.2% | -30.0% | -3.6% | -64.2% |
| Net Profit Margin | -91.5% | -1,251.3% | -953.7% | -159.1% | -5.6% | -206.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
AnaptysBio Inc. dividends
AnaptysBio Inc. has not paid dividends in the last 5 fiscal years.
Who owns AnaptysBio Inc.
- Insiders 5.63%
- Institutions 94.37%
- Public & others 0.00%
- Shares outstanding 29.9M
- Free float 20.5M
AnaptysBio Inc. company profile
- Company name
- AnaptysBio Inc.
- Ticker
- AN6.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 104
- Fiscal year end
- December
- Address
- 10770 Wateridge Circle, San Diego, CA, United States, 92121
- Phone
- 858 362 6295
- Website
- anaptysbio.com
About AnaptysBio Inc.
AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agreement with GSK plc to develop Jemperli as a monotherapy; and an exclusive license agreement with Vanda Pharmaceuticals Inc. for the development and commercialization of Quimilza. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
AnaptysBio Inc. management
4- Mr. Daniel R. FagaPresident, CEO & Director · born 1980
- Mr. Christopher M. MurphyChief Financial Officer · born 1984
- Ms. Beth MuellerSenior Vice President of Human Resources
- Mr. Benjamin StoneChief Business Officer · born 1991